Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib

While erlotinib is primarily administered to patients with non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations, it is also prescribed to patients with wild type (wt) EGFR in higher lines of treatment. However, there is no predictive marker for erlotinib effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Svaton, Martin, Fiala, Ondrej, Krakorova, Gabriela, Blazek, Jiri, Hurdalkova, Karolina, Barinova, Magda, Mukensnabl, Petr, Pesek, Milos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377161/
https://www.ncbi.nlm.nih.gov/pubmed/32724380
http://dx.doi.org/10.3892/ol.2020.11663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377161/
https://www.ncbi.nlm.nih.gov/pubmed/32724380
http://dx.doi.org/10.3892/ol.2020.11663

Ejemplares similares